Amarin sues FDA over off-label policy

Amarin sues FDA over off-label policy. Claims block on discussing off-label uses conflicts freedom of speech. ... Amarin is in the process of carrying out a cardiovascular outcomes study called REDUCE-IT to try to support its position, with results due

Teva launches first generic of GSK's Lovaza in US

Aside from GSK, the launch of a lower-priced Lovaza generic in the US also impacts Amarin Pharmaceuticals' Vascepa (icosapent ethyl), another fish oil-based therapy that is already on the

Amarin slides as FDA panel votes against fish oil therapy

Amarin slides as FDA panel votes against fish oil therapy. Advisory committee wants more data on Vascepa. ... Meanwhile, the cost of running REDUCE-IT is also a drain on Amarin's finances, with the bill for 2013 expected to come in at somewhere between

Senior changes for Forest and Amarin

Olanoff, effective December 31, while Amarin Corporation has announced that Joseph S Zakrzewski, an experienced biotech executive, has been appointed as its chief executive officer, effective immediately. ... Amarin. Prior to joining Amarin, Thero was

Prior to joining Pharmacopeia, Liebler served as senior vice-president of strategic Planning at Questcor and held executive-level positions with Enzon, Elan, Amarin and Athena Neurosciences.

Medius Deal Watch table for February 2015

aureus and Shigellosis. Corporate acquisition. 190. Amarin/ Eddingpharm. VASCEPA (icosapent ethyl) - triglyceride level reduction.

Pharma deals during November 2012

All may not be plain sailing with this BASF strategy however given the promise of a crowded market place with the anticipated introduction of Amarin's Vascepa next year, to be

Teva's Mark Salyer joins Amarin

Teva's Mark Salyer joins Amarin. Takes up newly-created chief commercial officer role. ... Amarin has appointed Mark Salyer to the newly-created position of chief commercial officer.